Clinigen plans first pharma float in five years
Clinigen, a fast-growing UK company, on Tuesday announced its intention to float on AIM in a deal that will be the first pharmaceuticals IPO in London for five years. It paves the way for the founder and chairman to exit the business.
According to reports, the listing will value the company at £170m. The companys EBITDA for the first half of this year was £17.3m, up 109% from last year. Revenues were up 135% in the first half of 2012.
Floating the group will allow for the departure of its founder
Please take a trial or subscribe to access this content.
Contact our subscriptions team to discuss your access: email@example.com
To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: firstname.lastname@example.org or find out more online here.